Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION

• DOI: 10.1186/s13063-022-06609-x
• Publication Date: 2022-08-19T11:04:34Z
• Authors: Jan Kloka; Benjamin Friedric...; Stephanie Dauth; Ann Christina Fol...; Anita Bulczak-Sch...; Maria J. G. T. Ve...; Francisco Maio Matos; Antoni Riera-Mestre; Antoinette D. I. ...; Edoardo De Robertis; Vilma Traskaite J...; Patrick Meybohm; Dana Tomescu; Karine Lacombe; Coen D. A. Stehouwer; Kai Zacharowski; ; Oliver Old; Markus Ketomaeki; Lea Grebe; Patrick Booms; Simone Lindau; Sebastian Zinn; Isabel Maushagen; Timo Wolf; Christoph Stephan; Cathy Weynants; Sylvia Daamen; Petra Wülfroth; Thomas Steiner; Marinus van Hulst; Peter Kranke; Sebastian Hottenrott; Tobias Schlesinger; Benedikt Schmid; Daniel Röder; Eva Kranke; Tobias Haas; Philipp Schlesinger; Magdalena Sitter; Davide Valeri; Raquel Torres Igl...; José María Mora-L...; Adriana Iriarte; Pau Cerdà; Neringa Vaguliene; Andrius Macas; Jolanta Litviniene; Kristina Balne; Catarina Monteiro; Inês Antunes Ferr...; Patrícia Couceiro; Pedro Soares; Sofia Beirão; Yasmine Abi Aad; Thibault Chiarabini; Mihai Popescu; C. J. H. van der ...
• Keywords: 2019-20 coronavirus outbreak; Coronavirus

More than 2.7 million hospitalizations of COVID-19-infected patients have occurred in Europe alone since the outbreak coronavirus 2020. Interventions against SARS-CoV-2 are still high need to prevent admissions ICUs worldwide. FX06, a naturally occurring peptide humans and other mammals, has potential reduce capillary leak by improving endothelial dysfunction thus preventing deterioration patients. With IXION, we want investigate FX06 disease progression hospitalized, non-intubated COVID-19